The Indication of Poor Prognosis by High Expression of ENO1 in Squamous Cell Carcinoma of the Lung.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
03
2021
revised:
27
06
2021
accepted:
19
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
The purpose of this study is to investigate the significance of alpha-enolase (ENO1) expression in squamous cell carcinoma of the lung (LUSC), its prognostic value, and prospective molecular mechanism. Using multiplatforms data, including in-house immunohistochemistry, in-house real-time fluorescence quantitative polymerase chain reaction (RT-qPCR), in-house microarray, and public high-throughput data, the expression significance and prognostic role of ENO1 in LUSC tissues were analyzed comprehensively. With the combination of all eligible cases, compared with 941 non-LUSC lung tissues, ENO1 was significantly overexpressed in 1163 cases of LUSC (standardized mean difference (SMD) = 1.23, 95% confidence interval (CI) = 0.76-1.70,
Identifiants
pubmed: 34504528
doi: 10.1155/2021/9910962
pmc: PMC8423576
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9910962Informations de copyright
Copyright © 2021 Wan-Ying Huang et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Comput Biol Chem. 2020 Dec;89:107383
pubmed: 33032037
Oncol Rep. 2019 Feb;41(2):939-953
pubmed: 30535503
J Hematol Oncol. 2017 Jan 13;10(1):16
pubmed: 28086938
Trends Mol Med. 2019 Jul;25(7):585-594
pubmed: 31155338
J Thorac Cardiovasc Surg. 2019 Jun;157(6):2354-2355
pubmed: 30503732
Cell Mol Life Sci. 2005 Apr;62(7-8):881-93
pubmed: 15868411
IET Syst Biol. 2020 Oct;14(5):252-260
pubmed: 33095746
Am J Transl Res. 2020 Apr 15;12(4):1275-1292
pubmed: 32355541
Cancer Med. 2018 Apr;7(4):1081-1092
pubmed: 29522283
Cell Death Differ. 2020 May;27(5):1660-1676
pubmed: 31685978
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3641-4
pubmed: 14506152
Zhongguo Fei Ai Za Zhi. 2010 Dec;13(12):1089-93
pubmed: 21159241
PLoS One. 2017 Feb 24;12(2):e0172674
pubmed: 28234977
Cancer Cell Int. 2020 Aug 14;20:392
pubmed: 32818022
Biomed Pharmacother. 2018 Sep;105:805-812
pubmed: 29913409
J Hematol Oncol. 2015 Mar 08;8:22
pubmed: 25887760
Respir Res. 2019 Mar 4;20(1):48
pubmed: 30832674
J Bras Pneumol. 2018 Jan-Feb;44(1):18-23
pubmed: 29538538
Cancer Manag Res. 2018 Nov 15;10:5735-5745
pubmed: 30532594
J Cell Biochem. 2019 Aug;120(8):12752-12761
pubmed: 30848500
FEBS Open Bio. 2020 Aug;10(8):1624-1641
pubmed: 32598517
Nat Commun. 2019 Jul 19;10(1):3200
pubmed: 31324812
Clin Cancer Res. 2006 Oct 1;12(19):5746-54
pubmed: 17020980
Gastroenterol Res Pract. 2018 Feb 1;2018:3842198
pubmed: 29483925
Biosci Rep. 2019 Sep 9;39(9):
pubmed: 31431517
Adv Med Sci. 2020 Sep;65(2):442-456
pubmed: 33059229
Oncol Lett. 2020 Apr;19(4):3189-3196
pubmed: 32256815
Biosci Rep. 2019 Nov 29;39(11):
pubmed: 30541900
Am J Transl Res. 2019 Aug 15;11(8):4835-4850
pubmed: 31497203
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Oncol. 2019 Mar 19;9:166
pubmed: 30941314
Life Sci. 2019 Dec 15;239:116873
pubmed: 31521689
Nat Rev Genet. 2019 Nov;20(11):631-656
pubmed: 31341269
Am J Transl Res. 2019 Jul 15;11(7):4470-4480
pubmed: 31396350
J Cell Mol Med. 2019 Oct;23(10):6578-6594
pubmed: 31449345
Cancer Biomark. 2017 Dec 6;20(4):539-546
pubmed: 28946554
Cell Death Dis. 2020 Oct 16;11(10):870
pubmed: 33067426
Cell Death Dis. 2018 Mar 1;9(3):347
pubmed: 29497031
Breast Cancer Res Treat. 2010 Jun;121(3):539-53
pubmed: 19655245
Cancer Manag Res. 2019 Nov 26;11:9969-9978
pubmed: 32063722
Cell Oncol (Dordr). 2019 Aug;42(4):571-578
pubmed: 30887286
J Cell Biochem. 2019 Nov;120(11):18714-18723
pubmed: 31218757